Industrial Scale-Up of Enantioselective Hydrogenation for the Asymmetric Synthesis of Rivastigmine

Pu-Cha Yan,Guo-Liang Zhu,Jian-Hua Xie,Xiang-Dong Zhang,Qi-Lin Zhou,Yuan-Qiang Li,Wen-He Shen,Da-Qing Che
DOI: https://doi.org/10.1021/op3003147
IF: 3.4
2013-01-01
Organic Process Research & Development
Abstract:Two efficient processes for the synthesis of rivastigmine, one of the most potent drugs for the treatment of mild-to-moderate dementia of the type presenting in Alzheimer's disease, has been developed. Of particular note is the processes used for the asymmetric hydrogenation by applying the highly efficient chiral spiro catalyst, Ir-SpiroPAP. The first route was easy to scale up in industry and provided the commercial intermediate (S)-3-(1-dimethylaminoethyl)phenol, 6, which is suitable for the manufacture of rivastigmine in active pharmaceutical ingredient (API) demand. The second route was convenient for operation and purification and completed the synthesis of rivastigmine (1) in four steps and 84% overall yield.
What problem does this paper attempt to address?